German CRO Proinnovera establishes U.S. foothold in North Carolina

Proinnovera named Sonja VanWye, from nearby Novella Clinical, as vice president of its U.S. clinical operations. (Pixabay)

The German dermatology CRO Proinnovera has opened a new U.S. base of operations through a wholly owned subsidiary based in Wilmington, North Carolina.

Proinnovera said it established an office in the U.S. in response to feedback from clients looking for a specialized global dermatology CRO in the country.

The subsidiary opened for business June 1, offering full-service clinical trial work in dermatology, immunology, inflammatory skin diseases, skin cancer and precancer, burns, wounds and aesthetics.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“We’re seeing the need for global reach of dermatology studies ever increasing. We want to meet this need by offering our clients a global presence with deep and responsive local expertise,” Marion Breuer, who shares the role of CEO with owner Burkhard Breuer, said in a statement.

Headquartered in Münster, Germany, Proinnovera also named Sonja VanWye as vice president of U.S. clinical operations. VanWye will be responsible for general management, team development, vendor selection and expanding the CRO’s footprint in the country.

VanWye was director of clinical operations and head of project management for Novella Clinical, based in the state’s Raleigh-Durham-Chapel Hill research triangle area, which had previously acquired TKL Research’s phase 2-4 clinical trials division to serve as its dermatology unit.

Suggested Articles

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

The Mayo Clinic tapped data analytics firm nference to build out an AI-powered engine to collate its years of clinical records and pathology work.

At the annual J.P. Morgan Healthcare Conference, major CRO Charles River Laboratories and Takeda announced a new preclinical tie-up.